Skip to main content
SpringerLink
Log in
Book cover

Thérapeutique du cancer pp 47–53Cite as

Hormonothérapie des cancers du sein

  • Chapter

  • 776 Accesses

Résumé

L’hormonothérapie est le plus ancien traitement médical des tumeurs solides puisque les premières observations de réponses tumorales après ovariectomie remontent au XIXe siècle

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Veronesi U, Boyle P, Goldhirsch A et al. (2005) Breast Cancer. Lancet 365: 1727–1741

    Article  PubMed  Google Scholar 

  2. Kaufman B, Mackey JR, Clemens MR et al. (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27: 5529–5537

    Article  PubMed  CAS  Google Scholar 

  3. Johnston S, Pippen J Jr, Pivot X et al. (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27: 5538–5546

    Article  PubMed  CAS  Google Scholar 

  4. Lonning PE (2009) Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer 45: 527–535

    Article  PubMed  CAS  Google Scholar 

  5. Baum M, Buzdar AU, Cuzick J et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131–2139

    Article  PubMed  CAS  Google Scholar 

  6. Robertson JF, Llombart-Cussac A, Rolski J et al. (2009) Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 27: 4530–4535

    Article  PubMed  CAS  Google Scholar 

  7. McCormack P, Sapunar F (2008) Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptorpositive advanced breast cancer. Clin Breast Cancer 8: 347–351

    Article  PubMed  CAS  Google Scholar 

  8. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717

    Article  Google Scholar 

  9. Coombes RC, Kilburn LS, Snowdon CF et al. (2007) Survival and Safety of exemestane vs tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369: 559–570

    Article  PubMed  CAS  Google Scholar 

  10. Jakesz R, Jonat W, Gnant M et al. (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366: 455–462

    Article  PubMed  CAS  Google Scholar 

  11. BIG 1-98 Colaborative Group (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361: 766–776

    Article  Google Scholar 

  12. Coates AS, Keshaviah A, Thürlimann B et al. (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol 25: 486–492

    Article  PubMed  CAS  Google Scholar 

  13. TEAM trial (2009) San Antonio Breast Cancer

    Google Scholar 

  14. Dowsett M, Cuzick J, Ingle J et al. (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28: 509–518

    Article  PubMed  CAS  Google Scholar 

  15. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for earlystage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9: 45–53

    Article  Google Scholar 

  16. Goss PE, Ingle JN, Martino S et al. (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97: 1262–1271

    Article  PubMed  CAS  Google Scholar 

  17. Mauriac L, Romieu G, Bines J (2009) Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Res Treat 117: 69–75

    Article  PubMed  CAS  Google Scholar 

  18. Combined Hormone Agents Trialists’ Group and the European Organization for Research and Treatment of Cancer (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19: 343–353

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie médicale, Hôpital Avicenne, 125, route de Stalingrad, 93009, Bobigny, Cedex

    L. Zelek

Authors
  1. L. Zelek
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France

About this chapter

Cite this chapter

Zelek, L. (2011). Hormonothérapie des cancers du sein. In: Thérapeutique du cancer. Springer, Paris. https://doi.org/10.1007/978-2-8178-0021-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0021-9_4

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0020-2

  • Online ISBN: 978-2-8178-0021-9

Publish with us

Policies and ethics

Search

Navigation